Ads
related to: treatment for mass on tail of pancreas
Search results
Results From The WOW.Com Content Network
sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. [ 27 ] [ 28 ] Sutent also has approval from the European Commission for the treatment of 'unresectable or metastatic, well-differentiated pancreatic neuroendocrine ...
It is usually solitary and found in the body or tail of the pancreas, and may be associated with von Hippel–Lindau syndrome. [2] In contrast to some of the other cyst-forming tumors of the pancreas (such as the intraductal papillary mucinous neoplasm and the pancreatic mucinous cystadenoma), serous cystic neoplasms are almost always entirely ...
Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy, palliative care, or a combination of these. [1] Treatment options are partly based on the cancer stage. [1] Surgery is the only treatment that can cure pancreatic adenocarcinoma, [12] and may also be done to improve quality of life without the potential for cure.
A pancreatic tumor is an abnormal growth in the pancreas. [1] In adults, almost 90% are pancreatic cancer and a few are benign. [1] Pancreatic tumors are rare in children. [1] Classification is based on cellular differentiation (ductal, acinar, neuroendocrine, other) and gross appearance (intraductal, cystic, solid). [1]
Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN tumors produce mucus, [1] and this mucus can form pancreatic cysts. [2] Although intraductal papillary mucinous neoplasms are benign tumors, they can progress to pancreatic cancer. [1]
Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. Amongst individuals undergoing surgical resection of a pancreatic cyst, about 23 percent were mucinous cystic neoplasms. These lesions are benign, though there is a high rate of progression to cancer. As such, surgery should be pursued when feasible.